Chr. Hansen Holding — Earnings Release 2016

Jul 5, 2016

Hoersholm, 2016-07-05 07:59 CEST (GLOBE NEWSWIRE) --

Company Announcement No. 11 / 2016

2015/16 YTD IN BRIEF

Strong organic revenue growth of 13% in the first nine months of 2015/16: Food
Cultures & Enzymes (13%), Health & Nutrition (2%) and Natural Colors (20%).
EBIT before special items increased by 18% to EUR 189 million. In Q3, organic
growth reached 12% and EBIT before special items increased by 11% to EUR 71
million.

EUR million Q3 Q3 Growth YTD YTD Growth
2015/16 2014/15 2015/16 2014/15

---

---

Revenue 249.8 228.1 10% 693.1 625.0 11%
EBIT before special items 71.0 63.8 11% 188.9 159.8 18%
Profit for the period 51.6 45.7 13% 127.9 111.0 15%
Free cash flow* 42.0 53.8 -22% 57.8 65.0 -11%

---

---

Organic growth 12% 7% 13% 9%
Gross margin 53.3% 52.4% 52.8% 51.4%
EBIT margin b.s.i. 28.4% 28.0% 27.2% 25.6%
ROIC excl. goodwill 36.0% 33.8%

---

• Before acquisitions, divestments and special items

“We continued to grow our business during Q3, with Food Cultures & Enzymes and
Natural Colors showing strong organic revenue growth. Both Food Cultures &
Enzymes and Natural Colors also delivered encouraging improvements in
profitability. We experienced modest growth in Health & Nutrition, as the
animal health business was negatively impacted by commodity prices for milk and
meat remaining at extraordinarily low levels. Despite the current pressure on
the agricultural sector, the long-term growth prospects for our animal health
business remain very positive,” says CEO Cees de Jong.

“During the past three months, we have made good progress with integrating NPC,
launched a second product for plant health with good first sales, and, within
the human microbiome area, successfully completed a clinical study showing a
positive physiological effect of the bacteria tested. Based on the results
achieved, we have moved to the next stage in our clinical development plan.
Finally, it is very encouraging to see a strong performance by our
bioprotective solutions for dairy and other food categories.”

OUTLOOK FOR 2015/16

The outlook for 2015/16 is unchanged compared to announcement on 7 April 2016.

Organic revenue growth: 10-12% (previously 10-12%)

Research & development expenditures incurred (% of revenue): around 7%
(previously around 7%)

EBIT margin before special items: above 2014/15 (previously above 2014/15)

Free cash flow before acquisitions, divestments and special items: above
2014/15 (previously above 2014/15)

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations
Tel: +45 4574 7618

Klara Halkjaer, Head of media relations

Tel: +45 4574 7474

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient
solutions for the food, nutritional, pharmaceutical and agricultural
industries. The products include cultures, enzymes, probiotics and natural
colors, and all solutions are based on strong research and development
competencies coupled with significant technology investments. Revenue in the
2014/15 financial year was EUR 859 million. The company has more than 2,600
dedicated employees in 30 countries and main production facilities in Denmark,
France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on
Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com.